Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers

Inclusion Criteria:

- Judged to be healthy by the Investigator on the basis of medical history, physical
examination and vital signs performed at Screening;

- Negative tests for Hepatitis B surface antigen (HBsAg), Hepatitis C antibody and Human
Immunodeficiency Virus (HIV) antibody;

- Screening electrocardiogram (ECG) deemed by the Investigator as having no clinically
significant findings;

- Use of medically effective contraception with a failure rate of < 1% per year when
used consistently and correctly from screening until 6 months following last dose or
be post-menopausal or be surgically sterile or have a partner who is sterile.

Exclusion Criteria:

- Pregnant or breastfeeding, or intending to become pregnant or father children within
the projected duration of the trial starting with the screening visit until 6 months
following last dose;

- Administration of an investigational product within 30 days of Day 0;

- Previous receipt of an investigational vaccine product for prevention of Lassa Fever;

- Fewer than two acceptable sites available for ID injection and EP considering the
deltoid and anterolateral quadriceps muscles;

- Current or anticipated concomitant immunosuppressive therapy.